Financial Comparison: Inovio Pharmaceuticals (NASDAQ:INO) & Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) and Inovio Pharmaceuticals (NASDAQ:INO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Valuation & Earnings

This table compares Insmed and Inovio Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42 million	45.26	-$1.28 billion	($4.11)	-30.58
Inovio Pharmaceuticals	$60,000.00	2,145.55	-$84.95 million	($0.91)	-1.37

Inovio Pharmaceuticals has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Insmed and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Volatility and Risk

Insmed has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Insmed and Inovio Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1	0	22	2	3.00
Inovio Pharmaceuticals	1	1	5	1	2.75

Insmed currently has a consensus price target of $205.52, suggesting a potential upside of 63.53%. Inovio Pharmaceuticals has a consensus price target of $3.17, suggesting a potential upside of 154.35%. Given Inovio Pharmaceuticals’ higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Insmed.

Summary

Inovio Pharmaceuticals beats Insmed on 8 of the 15 factors compared between the two stocks.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.